Skip to main content
. 2013 Jun 4;8(6):e64992. doi: 10.1371/journal.pone.0064992

Figure 1. The glycosylation of anti-gal IgG is altered with the development of fibrosis and cirrhosis.

Figure 1

Anti-gal IgG was purified from a pool (n = 20) of healthy individuals, pooled ( = 20) fibrotic individuals (stage 1–2) or pooled (n = 20) late stage fibrotic (cirrhotic) individuals (stage 5–6). Glycan analysis of the N-linked glycans associated with the heavy chain from the healthy individuals (panel A), the fibrotic individuals (panel B) or the late stage fibrotic individuals (panel C). For structures presented in panels A-C: FcA2G0, core fucosylated (1,6) agalactosylated biantennary glycan; FcA2G0B, core fucosylated (1,6) agalactosylated biantennary glycan with a bisecting N-acetylglucosamine (GlcNac); FcA2G1 (1,6) core fucosylated (1,6) biantennary glycan with a single galactose residue on the 1,6 arm; FcA2G1B (1,6) core fucosylated (1,6) biantennary glycan with a single galactose residue on the 1,6 arm and a bisecting GlcNac; FcA2G1 (1,3), core fucosylated (1,6) biantennary glycan with a single galactose residue on the 1,3 arm; FcA2G2, core fucosylated biantennary N-glycan (FcA2G2); FcA2G2B, bisected core fucosylated biantennary N-glycan.